CBCN had the opportunity to join researchers, clinicians, manufacturers and other patients at this annual European conference to learn the latest insights and findings in cancer research. Here’s the research that we found most interesting as breast cancer patients:
I remember sitting in the small room waiting for the doctor to come in. I was nervous but didn’t think anything was wrong. The doctor came in and asked how I was. I gave my usual cheery response that everything was good but added that “it depended on what he was going to tell me…ha ha ha”. I laughed but my jovial manner quickly subsided when my doctor sat down and the words “it’s not good” came out. My heart dropped. He then said, “It’s cancer”. My heart dropped again.
Last month, we had the opportunity to attend the 2018 San Antonio Breast Cancer Symposium (SABCS). Here’s some of the key highlights to come out of the conference.
In June 2015, I moved to London, Ontario and was recovering from a rather emotional and difficult time, having divorced in June 2014. I had moved from Sault Ste. Marie to be closer to my daughter with her husband and very young children. I would be seeing the rest of my family less often now – my parents, my two sisters, my daughter and her husband, and another granddaughter. and two step grandchildren.
Tell us a little bit about yourself, where you’re from, and your experience with breast cancer.
Last month, we connected with Alan from ODANO, the Oncology Drug Access Navigators of Ontario, to answer a few questions about who they are and how they help patients in Ontario access life-saving medications.
In August 2014 I found a lump in my left breast. This is unusual for inflammatory breast cancer (IBC), a rare and very aggressive cancer where cancer blocks the lymph vessels.
Inflammatory breast cancer (IBC) is a rare and aggressive form of the disease that doesn’t get a lot of attention. It’s tough to diagnose because of its unusual symptoms, and it’s more common in young women which makes it particularly tricky since the symptoms mimic that of mastitis, a common breast infection in new moms who breastfeed. Here’s what you need to know:
“Abject terror floating in the back of my head.” That’s how Shelley Moore of St. Albert, Alberta describes her reaction to her 2014 diagnosis of Stage II triple negative breast cancer.
Biosimilar therapies have already been in use in Canada for a few years, mostly in the chronic disease and supportive care settings. But soon they will be used for treating cancer as well. There isn’t a lot of information about these new oncology biosimilars and it’s important that breast cancer patients are aware of how their treatment plans may be impacted by these new therapies. We explore some of the emerging biosimilar therapies that will be used to treat cancer patients soon.
Earlier this month, the annual meeting for the American Society of Clinical Oncology was held in Chicago. Here, key research developments in every area of cancer care are shared with oncology professionals from around the world. We’ve compiled the top breast cancer highlights to come out of this year’s ASCO 2018 conference:
Now that you’ve learned more about biosimilars, it may also be of interest to learn what the physician perspective is. We connected with Dr. Sandeep Sehdev, a medical oncologist at the Ottawa Hospital, to get his perspective on biosimilars and what he thinks is important for patients to understand about them.
One of the most common complaints you hear from patients getting chemotherapy is brain fog. It's why it's most commonly known as "chemo brain". But what is it and why does it happen? And most importantly, how can it be managed?
Clinical trials play a big role in the discovery of new treatments for cancer. They help to determine the safety and effectiveness of potential new treatments. For metastatic patients, they can also potentially offer additional treatment options after the cancer has grown resistant to the standards of care.
Here are some highlights from the latest in breast cancer research:
For Jenn Abbott, finishing treatment for breast cancer is like a flying trapeze. Having received her “NED” (no evidence of disease), she is in mid-air, no longer holding on to the bar that represents the medical team that saved her life, while at the same time, not yet catching the second bar that represents the rest of her life after cancer. She is in limbo, facing post-traumatic stress disorder brought on by her cancer treatment which included five surgeries and a severe adverse reaction to chemotherapy that meant she had to stay in the hospital for two weeks. She feels PTSD after cancer treatment is real.
I’m from Ottawa. I was diagnosed de novo in March 2011 with metastatic breast cancer and metastasis to the bone. I am 53 years old. I am a mother, daughter, sister, artist, lesbian, atheist, and gardener.
Montreal resident Kelina feels like a “sitting duck” because although researchers are working hard to find treatments for triple negative breast cancer, there are no targeted therapies available to this cancer, which was diagnosed in December 2015.
Triple Negative Breast Cancer Day is an annual global event on March 3. This is a day for a global awareness and grassroots fundraising aimed at helping to eradicate triple-negative breast cancer and celebrating the courage and strength of triple negative breast cancer patients and survivors.
It’s good to set challenging goals.
I ran my first marathon the year I turned 50, and completed another two years later. I loved establishing training goals that would force me to push myself physically, and feeling healthy and strong as the result of running regularly. In November 2015, I decided on a new goal: to run another marathon in the fall of 2016, and complete it with a time fast enough to qualify for the Boston Marathon.